Nephrology

Myeloma

Questions discussed in this category

How do you approach treatment for patients with proliferative glomerulonephritis with monoclonal IgG deposits (PGNMID) with end-stage renal disease who are considering kidney transplant?

Most patients with PGNMID have no detectable disease in their marrow or blood and urine protein cannot adequately be monitored.

1 Answer available

How do you monitor multiple myeloma in patients receiving dialysis?

Since free light chains are removed by dialysis and SPEP can also be impacted, is there a reliable way to monitor patients with ESRD and MM?

1 Answer available

How is monoclonal gammopathy of renal significance (MGRS) different from myeloma kidney?

If there are light chain deposits on the kidney, is that conclusive of MGRS?

1 Answer available

What is your preferred first line regimen for myeloma with severe renal impairment, either on or off dialysis?

1 Answer available

Papers discussed in this category

Kidney international, 2018-07

Proliferative glomerulonephritis with monoclonal immunoglobulin G deposits is associated with high rate of early recurrence in the allograft.

BMC nephrology, 2019-02-14

Complete biopsy-proven resolution of deposits in recurrent proliferative glomerulonephritis with monoclonal IgG deposits (PGNMIGD) following rituximab treatment in renal allograft.

Related Topics in Nephrology